H&M, a global fashion giant, has already discontinued sizes 3XL and 4XL in women's dresses for spring/summer 2026, signaling a dramatic shift in the apparel industry. This reduction extends to XXL and XL, with these larger sizes also seeing cuts in inventory, according to The Guardian. Decisive moves by major retailers show a rapid industry-wide recalibration of sizing strategies, driven by evolving consumer body shapes.

The increasing use of GLP-1 medications is driving a demand for smaller clothing sizes, but the fashion industry's abrupt reduction in plus-size inventory is creating a significant challenge for those who still need or prefer larger options. This tension defines the current market, as brands attempt to predict future demand while serving present needs.

The fashion industry is undergoing a rapid and potentially exclusionary transformation in its sizing strategies, which could redefine body diversity in mainstream apparel and leave a substantial consumer segment struggling to find suitable clothing, particularly as the impact of weight loss drugs on fashion trends for 2026 becomes more apparent.

The GLP-1 Surge: Quantifying the Body Shift

Eighteen percent of US adults reported using GLP-1 drugs as of June 2025, a notable increase from 12% in 2024, according to The Guardian. The accelerating adoption rate shows a clear shift in the American population's health and physical characteristics. The overall US adult obesity rate appeared to peak at 39.9% in 2022, then dropped to 36.4% in 2023, as also reported by The Guardian, indicating a measurable, albeit modest, population-level change.

These figures suggest that while GLP-1 adoption is growing, the fashion industry's reaction, like Mango's 92% reduction in specific plus sizes for S/S 2026, appears disproportionately aggressive. This pace far outpaces the current or even projected short-term impact of these drugs on the general population's size distribution, suggesting an industry-wide overcorrection in anticipation of future shifts.

  • 18% — Percentage of US adults who reported using GLP-1 drugs as of June 2025, according to The Guardian.
  • 12% — Percentage of US adults using GLP-1 drugs in 2024, marking a significant increase from the previous year, according to The Guardian.
  • 39.9% — Peak US adult obesity rate observed in 2022, before a subsequent decline, as reported by The Guardian.
  • 36.4% — US adult obesity rate in 2023, reflecting a decrease from the prior year, according to The Guardian.
  • 0.5% — Mango's projected inventory share of new dresses in sizes 16 to 20 for spring/summer 2026, a drastic reduction from 6.6%, according to The Guardian.
  • 20% to 30% — Reduction in daily calorie consumption reported by GLP-1 takers, according to Catalina.